← All Nurix Therapeutics, INC filings

Nurix Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
NRIX
Nurix Therapeutics, INC
10-K: Nurix Therapeutics Advances Pipeline, Reports Increased Net Loss
Nurix Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $264.5 million for fiscal year 2025, while advancing its targeted protein degradation pipeline with key clinical milestones and strategic collaborations.
NASDAQ
NRIX
Nurix Therapeutics, INC
10-K: Nurix Therapeutics Reports Promising Clinical Data and Outlines Strategy for Growth in 2025
Nurix Therapeutics' 10-K filing highlights clinical progress, strategic plans for 2025, and financial collaborations aimed at advancing targeted protein degradation medicines.
NASDAQ
NRIX
Nurix Therapeutics, INC
10-K: Nurix Therapeutics Amends Sanofi Collaboration, Files Annual Report
Nurix Therapeutics has amended its collaboration agreement with Sanofi and filed its annual report on Form 10-K, detailing its financial position and clinical pipeline.